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Purpose: Skeletal muscle metastases (SMM) from non-small cell
lung cancer (NSCLC) are rarely encountered in clinical practice.
The prognosis and the adequate treatment are not known. The aim of
the study was to report our experience and to make an extensive
literature research concerning SMM.
Patients and Methods: In our unit, we identified 16 patients with
SMM in a 10-year period. The source of our literature search
(English and French language) was the international MEDLINE
database, and it exhausted all cited publications.
Results: We found 114 cases in the international literature (fol-
low-up period mentioned in 72 cases). Pain was the most frequent
symptom (83%). A mass was palpable in 78% of cases. The
diagnosis was obtained by either fine needle/surgical biopsy or wide
exeresis. The 5-year survival time was 11.5% with a median survival
of 6 months. The 5-year survival rates: number of SMM  single
versus multiple (13.6% [67 patients] versus 0% [21 patients]; p 
0.0022); disease-free interval (DFI) 6 months versus DFI 6
months (16.9% [18 patients] versus 9.1% [70 patients ]; p 
0.0458). We built three groups of prognostic significance: group I:
DFI 6 months and single metastasis; group II: DFI 6 months or
single metastasis; and group III: DFI 6 months and multiple
metastasis. The 5-year survival rates were: group I (14 patients):
group II (57 patients):group III (17 patients)  28%:6%:0% (p 
0.0000), and the median survival was 19:9:4 months.
Conclusion: The presence of SMM suggests an aggressive disease.
Selection of patients for a local treatment is an important factor that
determines survival. The ideal patient had a unique metachronous
metastasic deposit that can be treated by surgery.
Key Words: Non-small cell lung cancer, Skeletal muscle metasta-
sis, Surgery.
(J Thorac Oncol. 2009;4: 1236–1241)
Lung cancer is the leading cause of cancer-related deaths.Non-small cell lung cancer (NSCLC) accounts for ap-
proximately 80% of all cases. Nearly 50% of cases will be
metastatic at the time of diagnosis. The most common sites
are the brain (10%), bones (7%), the liver (5%), and the
adrenal gland (3%).1,2 When a metastasis is solitary in
nature (regardless of the site), patients seem to have a
better prognosis. Aggressive management has been asso-
ciated with improved survival rates.3–6
Although the skeletal muscle accounts for nearly 50%
of total body mass, metastatic disease is rarely encountered in
clinical practice. Almost all publications in the international
literature are case reports, and larger series of patients with
lung cancer origin do not exceed 10 cases.7–12
The purpose of this study is first to report our experi-
ence and second to make an extensive review of all published
cases in English and French literature concerning skeletal
muscle metastasis (SMM) from NSCLC.
PATIENTS AND METHODS
Sixteen patients were discovered having SMM in our
department more than a 10-year period (1998–2007). The
diagnosis was obtained by fine needle biopsy or surgical
specimen. For each patient, we collected: the demographic
data and clinical symptoms, the muscle metastasis (site,
number, size, and symptoms, disease-free interval [DFI]), the
histologic assessment of the tumors, the treatment applied for
the lung cancer, and/or muscle metastasis. DFI was defined as
follows: the interval between the primary NSCLC and the
SMM; prevalent SMM was the situation when the muscular
metastases were discovered before the primary NSCLC
(these cases were included in the synchronous group of
patients); synchronous  DFI 6 months; metachronous 
DFI 6 months. Clinical staging of the disease was made
according to the 1997 International Tumor, Node, Metastasis
staging system.13
Literature Research
The source of our literature search was the international
MEDLINE database, PubMed (a register of all publications
in English and French) using the search items “SMM” or
“muscle metastases” and “lung cancer” or “NSCLC.” More-
over, all the references listed from these articles were con-
firmed (case reports, review articles, etc.). The research
exhausted all cited publications.
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Statistical Methods
We included all well-documented patients (in terms of
follow-up) found in the international literature and in our
practice. The starting date for survival calculation was the
diagnostic date of SMM. The probability of survival and
different prognostic factors were calculated according to the
Kaplan-Meier method for univariate analysis and the Cox
proportional hazards model for multivariate analysis. A value
of the p  0.05 estimated by the log-rank test was regarded
as significant. The statistical analysis was performed with
SPSS software (SPSS Inc, Chicago, USA).
RESULTS
Our patients were 13 men and 3 women, averaging
60 years of age. Twenty-seven metastases were recorded:
7 in the muscles of the chest wall, 6 in the abdominal wall
(Figure 1), 11 in the lower limb (Figures 2 and 3), and 3 in
the upper limb. The patients’ characteristics are listed in
Table 1. The mean diameter (long axis) was 4 cm. The
primary lung tumor was treated anteriorly by surgery in
two cases, chemotherapy in three cases, both surgery and
chemotherapy in two cases and radio-chemotherapy in two
cases. In all other cases, because of the short DFI (1
month) or prevalent muscle metastasis, chemotherapy was
the chosen treatment. All patients died. The mean survival
time was 5.6 months after the diagnosis of SMM and 8.7
months after the primary NSCLC.
Literature Search
According to the literature research, 114 cases of SMM
have been described (period, 1946–2007). The patients’ char-
acteristics are detailed in Table 2. Most cases (97) were
treated for a single muscle metastasis. Pain was the most
frequent symptom (83%), and a mass was palpable in 78% of
cases. The size varied largely between 1 and 20 cm, median
of 6 cm. Local treatments were done in 80 cases.
FIGURE 3. 18 fluoro-deoxi-glucosis positron emission
tomoscintigraphy-scan of a muscle metastasis in the lower
limb (patient 11).
FIGURE 1. Computed tomography (CT) scan of a muscle
metastasis in the abdominal wall (patient 5).
FIGURE 2. Computed tomography (CT) scan of a muscle
metastasis in the lower limb (patient 6).
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Statistical Analysis
The follow-up period was recorded for only 72 cases in
the international literature. Including ours, it made an 88-
patient statistical database. The 1-year and 5-year survival
rates were 32.6% and 11.5%, respectively, with a median
survival of 6 months (Figure 4). The following parameters
did not significantly influence the survival of patients: age,
sex, presence of symptoms, site and size of metastasis,
histology, and TN staging of the NSCLC. The survival rate
was influenced by the number of SMM: single versus multi-
ple (13.6% [67 patients] versus 0% [21 patients] at 5 years;
p  0.0022) (Figure 5) and DFI 6 months versus DFI 6
months (16.9% [18 patients] versus 9.1% [70 patients] at 5
years; p 0.0458) (Figure 6). In the multivariate analysis, the
single metastasis (p  0.0016; 95% confidence interval: 1.43–
4.73) and a DFI 6 months (p  0.0339; 95% confidence
interval: 0.26–0.94) maintained the statistical significance. Us-
ing these two independent factors of prognostic significance, we
built three groups: group I: no risk factors (DFI 6 months
and single metastasis), 14 patients; group II: one risk factor
(DFI 6 months or single metastasis), 57 patients; and group
III: two risk factors (DFI 6 months and multiple metasta-
sis), 17 patients. The 5-year survival rates were group I:group
II:group III  28%:6%:0% (p  0.0000) (Figure 7) and the
median survival, 19:9:4 months.
We evaluated the prognostic significance of the treat-
ments applied. When local treatment was applied (with or
without chemotherapy), the 5-year survival was 14.4% (68
patients); when only chemotherapy or supportive care was
done, the 5-year survival rate was 0% (20 patients) (p 
0.0000). Comparing the local treatments, we had the follow-
ing survival rates at 5 years: surgery (17 patients) versus
radiotherapy (40 patients) versus combination (surgery 
radiotherapy) (11 patients)  28% versus 14.5% versus 0%
(p  0.5156).
DISCUSSION
According to Prior,14 the first description of muscle
metastasis was reported by Wittich in 1854, and Willis was
the first to report a muscle metastasis of lung origin. Despite
being highly vascular, the exact incidence is barely known. In
1950, Abrams et al.15 failed to mention this tissue as a site of
metastasis in his thorough study of 1000 consecutive autop-
sied cases. Willis16 observed only four instances in 500 cases
of carcinoma. Subclinical metastasis may indeed be more com-
mon than generally thought. One large autopsy study of 5298
people found that 6% involved SMM of the chest or abdominal
wall.17 Acinas-Garcia et al.18 reported an incidence of 17.5%.
Pearson19 systematically studied several muscles, arbitrarily
chosen, and he found a 16% incidence of SMM.
Nowadays autopsy on all cancer-related deaths is not
performed routinely. An important help is the 18 fluoro-deoxi-
glucosis positron emission tomoscintigraphy-scan mostly for
detecting subclinical metastasis.20,21 Since 2004 when this
imaging procedure was introduced into our practice, single
SMM has been rarely seen. Certainly, there are several
limitations concerning muscle enhancement in PET scan, so
we included in our study only the patients with computed
tomography (CT)-scan confirmation and a histologic sample
of one metastatic deposit.
There are several theories explaining muscle resistance
of metastatic disease. The most important hypotheses are
mechanical (muscle contraction, high tissue pressure,11 and
extremely variable blood flow22), metabolic (pH, lactic acid
production,23 and toxic-free radical oxygen11) or immuno-
logic (cellular and humoral immunity and hypersensitivity
TABLE 1. Patient’s Characteristics
No./Gender/Age Symptoms Size (cm) DFI (mo) TN Histology
Treatment
Survival (mo)Local General
1/M/67 P  M 5 7 T4N2 SqCC — CTh 7
2/M/69 P  M 9 4 T2N3 ADC S  RTh CTh 5
3/F/66 P 3 10 T3N1 SqCC RTh CTh 17
4/F/45 P 7 2 T3N2 SqCC — — 1
5/M/51 P  M 4 2 T2N1 SC S CTh 13
6/M/46 P  M 6; 5 1 T2N2 SC S CTh 3
7/M/66 P  M 5 pMM T2Nx ADC — — 1
8/M/52 M 12 pMM T4Nx SqCC S  RTh CTh 3
9/M/71 M 5 3 T1Nx SC S CTh 3
10/M/75 M 5;3 3 T2N2 LCC — CTh 2
11/M/65 P  M 2;2 pMM FNB Undif — CTh 3
12/M/54 M 5; 2; 2; 1; 1 1 T2N3 ADC — CTh 3
13/M/60 — 3 8 T2N0 ADC — CTh 8
14/F/50 — 3;2;2 8 T2N2 ADC — CTh 9
15/M/46 P  M 3;2;2 pMM T3N1 ADC RTh CTh 7
16/M/84 P  M 4 pMM T2Nx ADC S  RTh CTh 6
P, pain; M, mass; DFI, disease free interval; pMM, prevalent muscle metastasis; TN, TN staging; S, surgery; CTh, chemotherapy; RTh, radiation therapy; SqCC, squamous cell
carcinoma; ADC, adenocarcinoma; SC, sarcomatoïd carcinoma; LCC, large cell carcinoma; Undif, undifferentiated non-small cell lung cancer.
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reaction24). None of them can explain the full mechanism but
perhaps a combination of them.
The aim of this extensive review is to define the clinical
course and prognosis of SMM and what treatment should be use.
Almost 1/3 of metastases, in our experience, were discovered
before the lung cancer. In the international literature 1⁄2 of
metastasis are prevalent, 1⁄4 synchronous, and only 1⁄4 were
discovered more than 6 months after the treatment of the
primary NSCLC. These findings can be an argument for
particularly aggressive cancers. Most SMMs are clinically
palpable and painful. Histologic samples are easily obtained
under local anesthesia.
The most common appearance (83%) of the lesions on
contrast-enhanced helical CT is that of a rim-enhancing mass
with central hypoattenuation.25,26 Intramuscular abscesses
can have similar appearance, but the presence of acute focal
clinical findings, bacteremia and sepsis, clinical history of
intravenous drug abuse, and abscess is the likely diagnosis. In
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FIGURE 4. Overall survival rate.
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FIGURE 5. Overall survival rates according to the number
of muscle metastasis.
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FIGURE 6. Overall survival rates according to the disease-
free interval (DFI).
TABLE 2. Literature Search and Patient’s Characteristics
Characteristics Value No. cases
Age Median 58
Range 31–81
Sex Male 89
Female 17
8 NR
Number Single 97
2/3/4 8/5/2
Multiple 2
Site Abdominal wall 22
Chest wall 20
Upper limb 33
Lower limb 55
9 NR
Symptoms Mass 78
Pain 83
14 NR
DFI Prevalent 53
Synchronous 6 mo 19
Metachronous 6 mo 20
22 NR
Diagnosis Fine needle biopsy 53
Surgical biopsy 23
Wide exerexis 22
16 NR
Histology SqCC 43
ADC 48
SC 3
LCC 4
NSCLC 10
6 NR
Treatment Surgery 24
Radiation therapy 46
Combination 9
NR, Not recorded; DFI, disease free interval; SqCC, squamous cell carcinoma;
ADC, adenocarcinoma; SC, sarcomatoïd carcinoma; LCC, large cell carcinoma;
NSCLC, non-small cell lung cancer.
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the absence of clinical findings, CT detection of these lesions
may guide needle biopsy. Magnetic resonance imaging is the
technique of choice to characterize soft tissue lesion, but the
metastatic lesions show nonspecific characteristics: increased
signal intensity relative to skeletal muscle on T2-weighted
images, decreased signal intensity on T1-weighted images,
and heterogenous enhancement after gadolinium administra-
tion.27–30 The same characteristics apply to soft tissue sar-
coma. Although solitary muscle metastasis are rare, the com-
bination of a muscle mass with a solitary lung mass with or
without adenopathy is more likely to represent a lung cancer
metastasizing to the muscle. When patients with sarcoma
have shown lung metastasis, there has been usually more than
one lesion.
Almost all type of NSCLC can metastasize in the
muscle with no particular preferences (Figure 8). The prog-
nosis is obscure, most of the patients died with a median
survival of only 6 months. The role of local treatment in the
global survival is difficult to define. Surgery and/or radiother-
apy were applied because of the absence of other metastatic
deposits (the primary tumor being controlled). Otherwise, for
extensive disease, the patients benefited only chemotherapy
or supportive care. Our results showed that a particular set of
patients could benefit from local treatment if they had no risk
factors (single metastasis, DFI 6 months), with a median of
survival of 19 months. We found a slight difference (not of
statistical significance) of survival in the advantage of surgery.
There are several bias in our results because: most of
the reports are case reports, sometime with incomplete data,
rare pathology, and only 114 published cases in a 60-year
period (so difficulty to conduct a prospective study). Despite
that the present analysis gives some information of the
clinical and prognostic behavior of the SMM from NSCLC.
Half of them are prevalent painful masses. The presence of
SMM suggests an aggressive disease. Selection of patients
for a local treatment is an important factor that determines
survival. Unfortunately, the tumor and host factors that allow
local treatment to control a systemic disease are unknown.
Despite the limitations of a small study group, the ideal
patient had a unique metachronous metastasic deposit that
can be treated by surgery; in that case 1⁄4 of patients are still
alive after 5 years.
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